Rituximab biosimilar (Shanghai Henlius Biotech)

利妥昔单抗生物类似药（上海复宏汉霖生物）

Report date: 2026/04/13 20:02:18

Base Information

Drug NameRituximab biosimilar (Shanghai Henlius Biotech)
Drug Alias Name利妥昔单抗生物仿制药（上海复宏汉霖生物）汉利康AUDEXAHLX-01HLX-01-RA
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsArthritis, RheumatoidLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[5] 
Global Approved IndicationsLymphoma, Non-Hodgkin
Approved Indications in ChinaLymphoma, Non-Hodgkin
Original Approved Country/TerritoryMainland China
Original Approved Date2019/02/22
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Henlius Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesEurofarma Laboratorios SaAbbott Operations Uruguay SrlShanghai Henlius Biotech Inc +[4] 
Inactive CompaniesN/A
Active IndicationsArthritis, RheumatoidLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin
Inactive IndicationsLymphoma, FollicularLymphoma, B-Cell

Other Information

ATC CodeL01XC02
Related LinksN/A